Dupont Capital Management Corp reduced its stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Get Rating) by 25.1% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,108 shares of the biotechnology company's stock after selling 1,042 shares during the quarter. Dupont Capital Management Corp's holdings in Arrowhead Pharmaceuticals were worth $103,000 at the end of the most recent quarter.
A number of other institutional investors have also recently added to or reduced their stakes in the stock. NJ State Employees Deferred Compensation Plan bought a new position in Arrowhead Pharmaceuticals during the 3rd quarter worth $347,000. US Bancorp DE boosted its position in Arrowhead Pharmaceuticals by 39.2% during the 3rd quarter. US Bancorp DE now owns 22,362 shares of the biotechnology company's stock worth $740,000 after acquiring an additional 6,292 shares during the period. Van ECK Associates Corp acquired a new position in Arrowhead Pharmaceuticals during the 3rd quarter worth $52,000. Wipfli Financial Advisors LLC acquired a new position in Arrowhead Pharmaceuticals during the 3rd quarter worth $39,000. Finally, Nelson Van Denburg & Campbell Wealth Management Group LLC acquired a new position in Arrowhead Pharmaceuticals during the 3rd quarter worth $101,000. 65.46% of the stock is currently owned by institutional investors.
Get Arrowhead Pharmaceuticals alerts:Arrowhead Pharmaceuticals Stock Down 2.5 %
Shares of NASDAQ ARWR opened at $35.99 on Thursday. The stock has a market capitalization of $3.82 billion, a price-to-earnings ratio of -21.42 and a beta of 1.26. The stock's fifty day simple moving average is $33.93 and its 200 day simple moving average is $36.71. Arrowhead Pharmaceuticals, Inc. has a 52-week low of $26.81 and a 52-week high of $56.25.
Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Rating) last issued its earnings results on Monday, November 28th. The biotechnology company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.57) by ($0.24). The company had revenue of $31.58 million during the quarter, compared to analyst estimates of $107.60 million. Arrowhead Pharmaceuticals had a negative return on equity of 40.23% and a negative net margin of 71.01%. As a group, analysts anticipate that Arrowhead Pharmaceuticals, Inc. will post -0.59 earnings per share for the current year.Insider Buying and Selling
In other news, insider Martin Javier San sold 19,500 shares of the firm's stock in a transaction on Monday, November 21st. The stock was sold at an average price of $29.99, for a total value of $584,805.00. Following the completion of the sale, the insider now owns 91,500 shares of the company's stock, valued at $2,744,085. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, Director William D. Waddill sold 3,200 shares of the firm's stock in a transaction on Monday, January 9th. The stock was sold at an average price of $30.00, for a total value of $96,000.00. Following the completion of the sale, the director now owns 28,950 shares of the company's stock, valued at $868,500. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Martin Javier San sold 19,500 shares of the firm's stock in a transaction on Monday, November 21st. The stock was sold at an average price of $29.99, for a total value of $584,805.00. Following the completion of the sale, the insider now directly owns 91,500 shares of the company's stock, valued at approximately $2,744,085. The disclosure for this sale can be found here. Insiders have sold 109,966 shares of company stock worth $4,050,435 in the last three months. 3.20% of the stock is currently owned by insiders.
Wall Street Analyst Weigh In
A number of research analysts have issued reports on ARWR shares. B. Riley reduced their price target on Arrowhead Pharmaceuticals from $65.00 to $59.00 and set a "buy" rating for the company in a research report on Wednesday, November 30th. The Goldman Sachs Group reiterated a "buy" rating and set a $66.00 price target (up previously from $65.00) on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, November 30th. HC Wainwright dropped their price objective on Arrowhead Pharmaceuticals from $110.00 to $90.00 and set a "buy" rating on the stock in a research note on Tuesday, December 6th. Piper Sandler dropped their price objective on Arrowhead Pharmaceuticals from $64.00 to $55.00 in a research note on Monday, January 9th. Finally, StockNews.com started coverage on Arrowhead Pharmaceuticals in a research note on Wednesday, October 12th. They issued a "hold" rating on the stock. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $59.22.
Arrowhead Pharmaceuticals Profile
(Get Rating)
Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in phase 2b clinical trial for the treatment of dyslipidemia; ARO-HSD, which is completed phase 1/2 clinical trial to treat liver diseases; ARO-ENaC2, which is in pre-clinical stage for the treatment of dyslipidemia cystic fibrosis; ARO-C3 that is in phase 1/2a clinical trial to reduce production of complement component 3; ARO-DUX4, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH that is in phase 1 clinical trial to treat uncontrolled gout; ARO-COV, which is in pre-clinical stage for the treatment of COVID-19; ARO-RAGE, which is in phase 1/2a clinical trial to treat muco-obstructive or inflammatory pulmonary conditions; and ARO-MMP7 that is in phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis.
Recommended Stories
- Get a free copy of the StockNews.com research report on Arrowhead Pharmaceuticals (ARWR)
- Procter & Gamble Earnings: A Gamble Worth Taking
- Stocks Slide, Economic Report Paints Gloomy Picture For Economy
- What does Nu Holdings Stock Have To Do With Warren Buffett?
- J.B. Hunt Gets A Flat, Logistic Companies Come Into Focus
- Is Intel Stock On The Verge Of Breaking Out?
Want to see what other hedge funds are holding ARWR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Get Rating).
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.